Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 4.94 -3.89% -0.20
CLDX closed down 3.89 percent on Friday, March 22, 2019, on 1.38 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Extremely Strong Down Down Up
See historical CLDX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 22 Narrow Range Bar Range Contraction 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 21 Crossed Above 20 DMA Bullish -3.89%
Mar 21 Pocket Pivot Bullish Swing Setup -3.89%
Mar 21 Narrow Range Bar Range Contraction -3.89%
Mar 21 Wide Bands Range Expansion -3.89%
Mar 20 Spinning Top Other 3.13%

Older signals for CLDX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Treatment Of Cancer Immunotherapy Immune System Monoclonal Antibodies Cancer Treatments Antibody Drug Conjugates Seattle Genetics Cancer Research Amgen Advanced Breast Cancer Hematologic Cancers Recurrent Glioblastoma Targeted Immunotherapy Treatment Of Advanced Breast Cancer
Is CLDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 558.0
52 Week Low 4.38
Average Volume 279,537
200-Day Moving Average 79.6058
50-Day Moving Average 39.7521
20-Day Moving Average 5.0415
10-Day Moving Average 4.838
Average True Range 3.3769
ADX 80.65
+DI 7.6144
-DI 49.363
Chandelier Exit (Long, 3 ATRs ) -3.9157
Chandelier Exit (Short, 3 ATRs ) 14.5107
Upper Bollinger Band 5.7635
Lower Bollinger Band 4.3195
Percent B (%b) 0.43
BandWidth 28.642269
MACD Line -8.4097
MACD Signal Line -10.9415
MACD Histogram 2.5317
Fundamentals Value
Market Cap 634.01 Million
Num Shares 128 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -4.53
Price-to-Sales 32.43
Price-to-Book 1.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.50
Resistance 3 (R3) 5.53 5.38 5.41
Resistance 2 (R2) 5.38 5.24 5.36 5.38
Resistance 1 (R1) 5.16 5.15 5.08 5.13 5.34
Pivot Point 5.00 5.00 4.97 4.99 5.00
Support 1 (S1) 4.79 4.86 4.71 4.75 4.54
Support 2 (S2) 4.63 4.77 4.61 4.50
Support 3 (S3) 4.41 4.63 4.47
Support 4 (S4) 4.38